RESUMEN
Borreliosis is a common affliction in northern countries and its neurological manifestations often mislead trained clinicians. We present three cases of Lyme neuroborreliosis, with intrathecal synthesis of specific antibodies, lymphocytic meningitis and magnetic-resonance imaging (MRI) findings. Our description aims at illustrating the natural history of the infection, highlighting persistent intrathecal synthesis of anti-Borrelia antibodies months after treatment completion, and its clinical significance. We then review the literature on MRI findings in neuroborreliosis and the kinetics of intrathecal synthesis of specific anti-Borrelia antibodies.
Asunto(s)
Borrelia , Neuroborreliosis de Lyme , Anticuerpos Antibacterianos , Humanos , Inmunoglobulina G , Cinética , Neuroborreliosis de Lyme/diagnósticoAsunto(s)
Actinomicosis Cervicofacial/diagnóstico , Edema/diagnóstico , Cuello/patología , Infecciones por Pasteurellaceae/diagnóstico , Pérdida de Peso , Actinomicosis Cervicofacial/complicaciones , Aggregatibacter actinomycetemcomitans/aislamiento & purificación , Trastornos Relacionados con Cocaína/complicaciones , Diagnóstico Diferencial , Edema/patología , Hepatitis C/complicaciones , Dependencia de Heroína/complicaciones , Humanos , Enfermedad Relacionada con Inmunoglobulina G4/diagnóstico , Masculino , Persona de Mediana Edad , Infecciones por Pasteurellaceae/complicaciones , Enfermedades Torácicas/complicaciones , Enfermedades Torácicas/diagnóstico , Enfermedades Torácicas/microbiología , Tabaquismo/complicacionesRESUMEN
We undertook this study to determine the clinical, biologic, immunologic, and therapeutic factors associated with the prognoses of polyarteritis nodosa (PAN) and Churg-Strauss syndrome (CSS). Three hundred forty-two patients (260 with PAN, 82 with CSS) followed from 1980 to 1993 were included in a prospective study on prognostic factors. Two hundred eighty-eight of these patients were included in the prospective studies on PAN and CSS. Items to be considered for analysis were collected at the time of diagnosis, during the acute phase of the disease. A survival curve was plotted for each clinical and biologic symptom observed in PAN or CSS. Each treatment arm of the prospective therapeutic trials was also tested: 1) prednisone (CS) + oral cyclophosphamide (CYC) + plasma exchanges (PE) versus CS E, 2) CS + PE versus CS, 3) CS + oral CY versus CS + pulse CY, 4) CS + pulse CY + PE versus CS + pulse CY in severe PAN and CSS, and 5) PE + antiviral agents after short-term CS in hepatitis B virus-related PAN. Of the parameters thus evaluated, the following had significant prognostic value and were responsible for higher mortality: proteinuria > 1 g/d (p < 0.0001; relative risk [RR] 3.6), renal insufficiency with serum creatinine > 1.58 mg/DL (p < 0.02; RR 1.86), GI tract involvement (p < 0.008. RR 2.83 for surgery). Cardiomyopathy and CNS involvement were associated with a RR of mortality of 2.18 and 1.76, respectively; these were not statistically significant. Similar survival rates were obtained with the prospectively tested therapies. The five-factors score (FFS) we established considered the prognostic factors creatinemia, proteinuria, cardiomyopathy, GI tract involvement, and CNS signs. Multivariate analysis showed that proteinuria (due to vascular or glomerular disease) and GI tract involvement were independent prognostic factors. When FFS = 0 (none of the 5 prognostic factors present), mortality at 5 years was 11.9%; when FFS = 1 (1 of the 5 factors present), mortality was 25.9% (p < 0.005); when FFS > 2 (3 or more of the 5 factors present), mortality was 45.95% (p < 0.0001 between 0 and 2, p < 0.05 between 1 and 2). We conclude that an initial assessment of PAN or CSS severity enables outcome and mortality to be predicted. The FFS is a good predictor of death and can be used to help the clinician choose the most adequate treatment. Renal and GI signs are the most serious prognostic factors.
Asunto(s)
Síndrome de Churg-Strauss/diagnóstico , Inmunosupresores/uso terapéutico , Poliarteritis Nudosa/diagnóstico , Adolescente , Adulto , Anciano , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Síndrome de Churg-Strauss/clasificación , Síndrome de Churg-Strauss/terapia , Protocolos Clínicos , Ciclofosfamida/administración & dosificación , Ciclofosfamida/uso terapéutico , Femenino , Hepatitis B/complicaciones , Humanos , Inmunosupresores/administración & dosificación , Interferón-alfa/administración & dosificación , Interferón-alfa/uso terapéutico , Masculino , Persona de Mediana Edad , Intercambio Plasmático , Poliarteritis Nudosa/clasificación , Poliarteritis Nudosa/terapia , Prednisona/administración & dosificación , Prednisona/uso terapéutico , Pronóstico , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Tasa de Supervivencia , Resultado del Tratamiento , Vidarabina/administración & dosificación , Vidarabina/uso terapéuticoRESUMEN
Churg-Strauss syndrome (CSS) is a systemic vasculitis characterized by the presence of asthma, hypereosinophilia, and necrotizing vasculitis with extravascular eosinophil granulomas. In this retrospective study of 96 patients between 1963 and 1995, we analyzed clinical manifestations, identified prognostic factors, and assessed the long-term outcome. CSS was diagnosed when asthma, hypereosinophilia > 1,500/mm3 or > 10%, and clinical manifestations consistent with systemic vasculitis, with or without histologic evidence, were present. Asthma was the most frequently observed manifestation at presentation, with mononeuritis multiplex the second. Other common manifestations were weight loss, fever, myalgia, skin involvement, paranasal sinusitis, arthralgia, pulmonary infiltrate, and gastrointestinal involvement. Mean eosinophilia at presentation was 7.193 +/- 6.706/mm3; ANCA, present in 20 of 42 (47.6%) patients, predominantly gave the perinuclear labeling pattern. All the patients were treated with corticosteroids alone or in combination with cyclophosphamide or plasma exchanges. Clinical remission was obtained in 91.5%; 22 (25.6%) patients relapsed. Twenty-three patients died during follow-up: 11 of these deaths were directly due to vasculitis. The presence of severe gastrointestinal tract or myocardial involvement was significantly associated with a poor clinical outcome. The long-term prognosis of CSS is good and does not differ from that of polyarteritis nodosa, although most patients need low doses of oral corticosteroids for persistent asthma, even many years after clinical recovery from vasculitis.
Asunto(s)
Síndrome de Churg-Strauss/terapia , Adolescente , Adulto , Anciano , Antiinflamatorios/uso terapéutico , Causas de Muerte , Síndrome de Churg-Strauss/complicaciones , Síndrome de Churg-Strauss/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Intercambio Plasmático , Pronóstico , Recurrencia , Inducción de Remisión , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Esteroides , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
Seven patients, 4 women and 3 men afflicted with severe progressive systemic sclerosis (PSS) were treated with Plasma Exchange after failure of different other treatment. All patients presented Raynaud phenomenon and arthritis, 6 patients presented extensive skin lesions, 5 of them digestive manifestations, 3 pulmonary fibrosis. In one case PSS was associated with polymyositis, one patient presented bilateral recurrent cornea ulcerations, (Sjögren Syndrome++) and one patient numerous skin ulcerations. In 5 patients adjuvant corticosteroid therapy was given during the course of PE. In 3 patients PE must be stopped after one or two sessions because of insufficient venous access. Among the 4 other patients 8 to 20 PE were performed: the patient with cornea ulcerations became blind during the treatment, skin ulcerations and severe Raynaud phenomenon did not improved in two other patients. Benefit of PE was noted in only one patient with regressive myositis, and improvement of articular and cutaneous symptoms. Therefore, PE are not useful in most patients afflicted with PSS, they are difficult to realize in numerous patients and did not improve clinical symptoms in most cases.
Asunto(s)
Intercambio Plasmático , Esclerodermia Sistémica/terapia , Adolescente , Femenino , Humanos , Masculino , Persona de Mediana Edad , Intercambio Plasmático/efectos adversosRESUMEN
Sensory neuropathy of trigeminal nerve is one of the neurological complications of systemic diseases, particularly scleroderma. Three cases are reported in which onset occurred at different stages of the disease, the main symptom being painful dysesthesias. All three branches of the trigeminal nerve may be affected but a preference is apparent for V2 and V3. Signs are usually limited to hypoesthesia and the chronic course is influenced little by treatment.
Asunto(s)
Esclerodermia Sistémica/complicaciones , Sensación , Nervio Trigémino , Enfermedades de los Nervios Craneales/complicaciones , Enfermedades de los Nervios Craneales/fisiopatología , Electrofisiología , Femenino , Humanos , Persona de Mediana Edad , Esclerodermia Sistémica/diagnóstico , Esclerodermia Sistémica/tratamiento farmacológicoRESUMEN
Recurrent thromboembolic accidents are frequent complications of Behçet's disease. Ten patients were investigated, 5 of them during an acute exacerbation of the disease. Abnormal responses to the venostasis test and to DDAVP (i.v.) were demonstrated in acute cases. Factor VIII activities after DDAVP were increased in all 10 patients, which suggests that the response of the vascular endothelium to the stimulus was normal and that a fibrinolytic system inhibitor may be present in the plasma of some patients.
Asunto(s)
Arginina Vasopresina , Síndrome de Behçet/sangre , Desamino Arginina Vasopresina , Fibrinólisis , Venas/fisiología , Adolescente , Adulto , Pruebas de Coagulación Sanguínea , Niño , Factor VIII/metabolismo , Femenino , Humanos , Infusiones Parenterales , Masculino , Persona de Mediana Edad , Seroglobulinas/metabolismoRESUMEN
The treatment and prognosis of periarteritis nodosa associated with hepatitis B virus were reconsidered from a series of 13 patients representing 32.5 per cent of the 40 patients with periarteritis nodosa admitted during the same period. HBs and HBe antigens were present in every case, and hepatitis B virus replication was demonstrated by the finding of viral DNA in serum. One patient had anti-HBc IgM's. Five patients were treated with corticosteroids, cyclophosphamide and occasional plasma exchanges. All were cured or achieved complete remission. Eight patients were treated with plasma exchanges and vidarabine, either as first-line therapy (3 cases) or after failure of corticosteroids and/or immunosuppressants (5 cases). This treatment was clinically effective in 5/8 cases, including 3 with seroconversion. The 2 patients in whom the combined treatment failed were given corticosteroids; one of them also had plasma exchanges. The 8th patient died after a few days of treatment. Eleven of the 13 patients are still alive and either cured or in complete remission. Two patients who developed severe chronic hepatitis after steroids were discontinued received vidarabine alone: arrest of viral replication was obtained in both cases, with emergence of an anti-HBe (but not anti-HBs) antibody. The overall positive virological response rate to vidarabine alone or combined with plasma exchanges was 50 per cent. When vidarabine was prescribed as treatment of acute periarteritis nodosa (the 2 cases where it was used for chronic hepatitis being excluded), this response rate was 37.5 per cent. This, in patients with periarteritis nodosa associated with hepatitis B virus immunosuppressive drugs should be withdrawn and replaced by plasma exchanges and antiviral agents. This would be the first-line treatment to be replaced by corticosteroid therapy if it fails.
Asunto(s)
Hepatitis B/complicaciones , Poliarteritis Nudosa/etiología , Terapia Combinada , Ciclofosfamida/uso terapéutico , Estudios de Seguimiento , Hepatitis B/terapia , Humanos , Intercambio Plasmático , Poliarteritis Nudosa/terapia , Prednisona/uso terapéutico , Pronóstico , Vidarabina/uso terapéuticoRESUMEN
Ten patients with severe systemic diseases, including systemic lupus erythematosus (n = 2), polymyositis (n = 2), essential mixed cryoglobulinaemia (n = 2), rheumatoid arthritis vasculitis (n = 3) and Wegener's granulomatosis (n = 1), were treated with 3 consecutive plasma exchanges synchronized with pulse cyclophosphamide. This therapeutic regimen was applied every 4 weeks initially and thereafter every 6 weeks in case of positive response after the first 3 cycles; it was combined in all patients with corticosteroid therapy. The treatment was administered for severe flare-up of the disease in 7 patients and for failure of previous treatments, including corticosteroids, cyclophosphamide and plasmapheresis, in 3 patients. Three kinds of response were observed: lasting complete remission without relapse after synchronization had ceased in 4 patients, partial clinical remission with post-synchronization relapse in 5 patients, and primary failure without any clinical response to treatment in only 1 patient. These results suggest that repeated plasma exchanges synchronized with cyclophosphamide are effective against progressive autoimmune diseases and in cases where conventionally administered immunosuppressive treatments had failed. However, this type of treatment cannot prevent long-term relapses, and only a prospective study can evaluate its success in terms of survival.
Asunto(s)
Enfermedades Autoinmunes/terapia , Ciclofosfamida/uso terapéutico , Intercambio Plasmático , Adulto , Anciano , Enfermedades Autoinmunes/sangre , Terapia Combinada , Ciclofosfamida/administración & dosificación , Femenino , Humanos , Inyecciones a Chorro , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de TiempoAsunto(s)
Síndrome de Churg-Strauss/terapia , Poliarteritis Nudosa/terapia , Anticuerpos Anticitoplasma de Neutrófilos , Autoanticuerpos/sangre , Síndrome de Churg-Strauss/patología , Ciclofosfamida/uso terapéutico , Hepatitis B/tratamiento farmacológico , Anticuerpos contra la Hepatitis B/sangre , Antígenos e de la Hepatitis B/sangre , Virus de la Hepatitis B/inmunología , Humanos , Intercambio Plasmático , Poliarteritis Nudosa/microbiología , Poliarteritis Nudosa/patología , Prednisona/uso terapéutico , Pronóstico , Estudios Prospectivos , Vidarabina/uso terapéuticoAsunto(s)
Eritema Nudoso/terapia , Lepra/terapia , Intercambio Plasmático , Adulto , Humanos , MasculinoAsunto(s)
Infecciones por VIH/complicaciones , Neuritis Óptica/etiología , Adulto , Humanos , MasculinoRESUMEN
The effects of estradiol, which are requisite for the normal occurrence of events related to reproduction, are not restricted to that field. They play a part in the overall trophicity of the female organism. On the other hand, relative or absolute estrogen hyperactivity results in harmful clinical effects and in disastrous cellular consequences, i.e. initiation or promotion of genital carcinomas. After a review of the different steps of the synthesis and action of estradiol, the various compounds that are active on these steps are considered: antigonadotropes (norsteroid progestogens, androgens, danazol, prolactin, corticosteroids, LHRH), inhibitors of estrogen synthesis (aminogluthetimide and testolactone), compounds that increase catabolism (progestogens), and antagonists of the cellular effect of estradiol (tamoxifen, nafoxidin, clomifen, progesterone, progestogens and androgens). The putative or established site of action and the main aspects of therapeutic use are given for each substance.
Asunto(s)
Antagonistas de Estrógenos/farmacología , Aminoglutetimida/farmacología , Andrógenos/farmacología , Clomifeno/farmacología , Antagonistas de Estrógenos/uso terapéutico , Estrógenos/biosíntesis , Estrógenos/fisiología , Femenino , Hormona Liberadora de Gonadotropina/farmacología , Humanos , Hidrocortisona/farmacología , Progestinas/farmacología , Prolactina/farmacología , Receptores de Estrógenos/metabolismoRESUMEN
OBJECTIVE: treatment of HIV-related vasculitis, avoiding prolonged immunosuppressive therapy. DESIGN: prospective pilot study of HIV-related neurological vasculitis. PATIENTS: two HIV-infected patients with histologically proven vasculitis. INTERVENTION: short-term corticosteroid followed by zidovudine combined with plasmapheresis. MAIN OUTCOME MEASURES: clinical, biological, immunological and electromyographic evaluation. RESULTS: complete neurological recovery. CONCLUSION: excellent tolerance and efficacy of combined zidovudine and plasmapheresis therapy in peripheral neurological HIV-related vasculitis.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/terapia , Plasmaféresis , Prednisona/uso terapéutico , Vasculitis/terapia , Zidovudina/uso terapéutico , Adulto , Terapia Combinada , Seropositividad para VIH , Humanos , Masculino , Enfermedades del Sistema Nervioso Periférico/terapia , Estudios ProspectivosRESUMEN
OBJECTIVE: To study the nature and incidence of gastrointestinal (GI) manifestations in polyarteritis nodosa (PAN) and Churg-Strauss syndrome (CSS) and define their therapeutic and prognostic implications. METHODS: Fifty-three patients (29 males, 24 females) affected with PAN or CSS and followed in our institution were included in a retrospective study. Patients were divided into 2 groups: patients without GI manifestations (group A) and patients with GI manifestations (group B). Among patients with GI manifestations we have studied a subgroup with a possibly poorer prognosis in whom the following symptoms were present: GI tract hemorrhage, intestinal perforation, digestive tract surgery due to PAN manifestations, intractable abdominal pain and weight loss greater than 20% of normal weight due to GI tract ischemia. RESULTS: The clinical manifestations were those that are classically encountered in PAN and CSS. Every patient fulfilled the American College of Rheumatology (ACR) criteria for PAN and CSS. Thirty-five patients without GI manifestations were included in group A and 18 patients (34%) with GI manifestations in group B. The mean age of the group at the time of diagnosis was 56.9 +/- 19.1 years (range: 21-71 years) in group A and 47.5 +/- 16.8 years (range: 12-82) in group B. GI manifestations were considered as one of the symptoms revealing PAN in 7 (13.2%) cases. Six of the 18 patients with GI manifestations had definite organ involvement related to vasculitis. Abdominal pain without characteristic organ involvement or surgical emergency was present in 12/18 patients. HBV infection was more frequently observed in group B than in group A. Survival curves showed that at 10 years, 80% of the patients in group A were alive versus 67% in group B (P not significant). For the 9 patients with severe GI manifestations, the survival curves showed that, at 10 years, 44% of them were alive versus 80% in the other group A (p < 0.001). CONCLUSIONS: GI manifestations are frequent in PAN and CSS and were present in 34% of our patients. Prognosis of PAN with GI manifestations is not statistically different than in PAN without GI involvement, except for patients with severe digestive complications.